Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Insight – The promise of orexin antagonists

This article was originally published in Scrip

Executive Summary

July's announcement of a $146 million-plus deal between GlaxoSmithKlineand the Swiss biopharmaceutical companyActelion, to collaborate on the development and commercialisation of orexin antagonist almorexant, has thrown the whole area of orexin research under the spotlight. Almorexant is in Phase III trials as a treatment for primary insomnia, but the potential applications of orexin antagonists extend beyond just the management of sleep disturbances.

You may also be interested in...



2011 Scrip Asia 100 - Abbott bullish about India but must work hard to retain crown

One year after acquiring Piramal's Domestic Formulations business in a deal that made it India's largest pharmaceutical player, Abbott remains confident about its growth prospects in India, where it hopes to be generating $2.5 billion in sales by 2020. But facing fierce competition from domestic firms, Abbott isn't about to get complacent, Michael Warmuth, senior VP of the company's Established Products Division, tells Pete Chan. This article is part of the 2011 Scrip Asia 100.

2011 Scrip Asia 100 - Asia life science-focused VC firms

Asia life science-focused VC firms*

2011 Scrip 100: Re-engineering Roche

Roche is overhauling its cost structure to produce a leaner organisation better equipped to focus on the business of pharmaceutical innovation. It is also investing heavily in China, turning its Shanghai operations into a centre for everything from commercial manufacturing and research to partnering, licensing and strategic planning. Pascal Soriot, chief operating officer of Roche Pharmaceuticals, speaks to Pete Chan in an exclusive interview.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133060

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel